Indonesia vs Kenya: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Indonesia
0.7%
in 2024
Kenya
0.7%
in 2024
Indonesia rank
43rd
Kenya rank
43rd
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Indonesia
- Kenya
How they compare
Indonesia currently reports 0.7% against 0.7% in Kenya, a difference of 0.0%.
Across all 10 years both countries report, Kenya has been ahead every year.
Indonesia ranks 43rd and Kenya ranks 43rd of 215 countries.
Kenya has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Indonesia | Kenya | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.9% | 1.1% | 0.2% | Kenya |
| 2020s | 0.8% | 0.9% | 0.0% | Kenya |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Indonesia or Kenya?
- Indonesia, at 0.7% against 0.7% in Kenya as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Indonesia and Kenya?
- 0.0%, with Indonesia ahead.
- How many years of comparable data are there for Indonesia and Kenya?
- 10 years are reported by both, from 2015 to 2024.
- How do Indonesia and Kenya rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Indonesia ranks 43rd and Kenya ranks 43rd of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.